

# Jalid Sehouli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5250077/publications.pdf>

Version: 2024-02-01

238  
papers

6,586  
citations

87723

38  
h-index

91712

69  
g-index

244  
all docs

244  
docs citations

244  
times ranked

8435  
citing authors

#	ARTICLE	IF	CITATIONS
1	Quality assurance and improvement in oncology using guideline-derived quality indicators – results of gynaecological cancer centres certified by the German cancer society (DKG). <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1703-1715.	1.2	2
2	Surgery due to mechanical bowel obstruction in relapsed ovarian cancer: clinical and surgical results of a bicentric analysis of 87 patients. <i>Archives of Gynecology and Obstetrics</i> , 2022, 305, 963-968.	0.8	6
3	Impact of COVID-19 on gynaecological patient care: results of patient’s survey with 327 patients. <i>Archives of Gynecology and Obstetrics</i> , 2022, 305, 389-395.	0.8	1
4	Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study. <i>ESMO Open</i> , 2022, 7, 100311.	2.0	7
5	Lipid reprogramming induced by the TFEB-ERR $\alpha$ axis enhanced membrane fluidity to promote EC progression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 28.	3.5	16
6	Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study. <i>Cancers</i> , 2022, 14, 418.	1.7	0
7	Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer. <i>PLoS ONE</i> , 2022, 17, e0262770.	1.1	3
8	Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy. <i>JCI Insight</i> , 2022, 7, .	2.3	36
9	In Situ N-Glycosylation Signatures of Epithelial Ovarian Cancer Tissue as Defined by MALDI Mass Spectrometry Imaging. <i>Cancers</i> , 2022, 14, 1021.	1.7	13
10	Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial. <i>Cancers</i> , 2022, 14, 1189.	1.7	3
11	Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study. <i>Cancers</i> , 2022, 14, 1780.	1.7	4
12	Clinical value of pre-operative scoring systems to predict leiomyosarcoma: results of a validation study in 177 patients from the NOGGO-REGSA Registry. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2021-003334.	1.2	3
13	Genotype-specific high-risk human papillomavirus infections and risk factors for cervical dysplasia in women with human immunodeficiency virus in Germany: results from a single-center cross-sectional study. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 716-723.	1.2	3
14	Reconstructive Surgery versus Primary Closure following Vulvar Cancer Excision: A Wide Single-Center Experience. <i>Cancers</i> , 2022, 14, 1695.	1.7	2
15	Ten years of live surgical broadcast at Charit–MAYO conferences (2010–2019): a systematic evaluation of the surgical outcome. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2021-003173.	1.2	2
16	Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer—Impact for Diagnosis and Treatment Monitoring. <i>Cancers</i> , 2022, 14, 168.	1.7	5
17	Blockade of ALDH in Cisplatin-Resistant Ovarian Cancer Stem Cells In Vitro Synergistically Enhances Chemotherapy-Induced Cell Death. <i>Current Oncology</i> , 2022, 29, 2808-2822.	0.9	10
18	ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5617-TPS5617.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Can Fried Frailty Score predict postoperative morbidity and mortality in gynecologic cancer surgery? Results of a prospective study. <i>Journal of Geriatric Oncology</i> , 2021, 12, 428-433.	0.5	8
20	Perspectives, fears and expectations of patients with gynaecological cancers during the COVID-19 pandemic: A Pan-European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGE). <i>Cancer Medicine</i> , 2021, 10, 208-219.	1.3	69
21	Preoperative quality of life as prediction for severe postoperative complications in gynecological cancer surgery: results of a prospective study. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 1057-1063.	0.8	10
22	Evaluation of Biomarkers in Myoma Patients: A Prospective Study Investigating the Role of LDH, CA 125, and IGF-1 after Uterus-Preserving Surgical Therapy. <i>Gynecologic and Obstetric Investigation</i> , 2021, 86, 100-107.	0.7	2
23	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. <i>Radiotherapy and Oncology</i> , 2021, 154, 327-353.	0.3	96
24	Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 713-720.	1.2	7
25	Effects of sarcopenia and malnutrition on morbidity and mortality in gynecologic cancer surgery: results of a prospective study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 393-402.	2.9	24
26	Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HR-QoL) in Patients with Ovarian Cancer: What Is Different Compared to Healthy Women?. <i>Cancers</i> , 2021, 13, 631.	1.7	4
27	When and how should peritoneal endometriosis be operated on in order to improve fertility rates and symptoms? The experience and outcomes of nearly 100 cases. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 143-155.	0.8	24
28	ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 153-190.	1.4	99
29	Secondary malignancies in long-term ovarian cancer survivors: results of the "Carolin meets HANNA"™ study. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 709-712.	1.2	5
30	Impact of health-related quality of life (HRQoL) on short-term mortality in patients with recurrent ovarian, fallopian or peritoneal carcinoma (the NOGGO-AGO QoL Prognosis-Score-Study): results of a meta-analysis in 2209 patients. <i>ESMO Open</i> , 2021, 6, 100081.	2.0	5
31	A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer. <i>Cancers</i> , 2021, 13, 1764.	1.7	7
32	Plasma calcitonin gene-related peptide (CGRP) in migraine and endometriosis during the menstrual cycle. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1251-1259.	1.7	13
33	Frailty Index for prediction of surgical outcome in ovarian cancer: Results of a prospective study. <i>Gynecologic Oncology</i> , 2021, 161, 396-401.	0.6	20
34	Results of a German wide survey towards current surgical approach in early stage cervical cancer NOGGO MONITOR 11. <i>Scientific Reports</i> , 2021, 11, 9774.	1.6	4
35	Gynecologic oncology on the global health agenda: A wake-up call. <i>Gynecologic Oncology</i> , 2021, 161, 336-338.	0.6	3
36	The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium. <i>Cancers</i> , 2021, 13, 2613.	1.7	10

#	ARTICLE	IF	CITATIONS
37	Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC) - analysis of the AGO-CaRE-1 study. <i>Gynecologic Oncology</i> , 2021, 161, 442-448.	0.6	4
38	Sexual, bladder and bowel function following different minimally invasive techniques of radical hysterectomy in patients with early-stage cervical cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 2335-2343.	1.2	8
39	The systemic treatment of recurrent ovarian cancer revisited. <i>Annals of Oncology</i> , 2021, 32, 710-725.	0.6	61
40	Chondroitin Sulfate Disaccharides, a Serum Marker for Primary Serous Epithelial Ovarian Cancer. <i>Diagnostics</i> , 2021, 11, 1143.	1.3	3
41	Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1791-1802.	1.3	11
42	ECOG and BMI as preoperative risk factors for severe postoperative complications in ovarian cancer patients: results of a prospective study (RISC-GYN trial). <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 1323-1333.	0.8	13
43	EUS-guided Transgastric Drainage to Manage a Postoperative Pancreatic Fistula After Distal Pancreatectomy and Splenectomy in Recurrent Ovarian Cancer: A Case Report. <i>Anticancer Research</i> , 2021, 41, 3649-3656.	0.5	2
44	Selective Internal Radiation Therapy in Breast Cancer Liver Metastases: Outcome Assessment Applying a Prognostic Score. <i>Cancers</i> , 2021, 13, 3777.	1.7	5
45	Survival outcomes of women with grade 3 endometrioid endometrial cancer: the impact of adjuvant treatment strategies. <i>Archives of Gynecology and Obstetrics</i> , 2021, , 1.	0.8	1
46	European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1199-1206.	1.2	44
47	Functional changes of immune cells: signal of immune tolerance of the ectopic lesions in endometriosis?. <i>Reproductive BioMedicine Online</i> , 2021, 43, 319-328.	1.1	11
48	Bevacizumab Combined with Platinum-Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients. <i>Cancers</i> , 2021, 13, 4739.	1.7	2
49	Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e37.	1.0	5
50	Lymphovascular space invasion and Ki67 as predictors of lymph node metastasis in primary low grade serous ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 98-103.	1.2	2
51	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 12-39.	1.2	859
52	186...Surgical outcome as prognostic factor in different histologic subtypes of ovarian carcinoma-analysis of 7 phase III trials by AGO Studygroup + ENGOT. , 2021, , .		1
53	Sentinel Lymph Node Staging with Indocyanine Green for Patients with Cervical Cancer: The Safety and Feasibility of Open Approach Using SPY-PHI Technique. <i>Journal of Clinical Medicine</i> , 2021, 10, 4849.	1.0	2
54	Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 465-472.	0.6	4

#	ARTICLE	IF	CITATIONS
55	Biological Impact of Unilateral Oophorectomy: Does the Number of Ovaries Really Matter?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 331-338.	0.8	9
56	Deciphering the Role of Humoral and Cellular Immune Responses in Different COVID-19 Vaccines—A Comparison of Vaccine Candidate Genes in Roborovski Dwarf Hamsters. <i>Viruses</i> , 2021, 13, 2290.	1.5	7
57	Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer—A Study of the OVCAD Consortium. <i>Cancers</i> , 2021, 13, 5865.	1.7	3
58	European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1508-1529.	1.2	13
59	Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 2123-2131.	13.9	144
60	Neurogenic Inflammation in the Context of Endometriosis—What Do We Know?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13102.	1.8	19
61	Dilution of Molecular—Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 213-219.	3.2	12
62	Anxiety of myoma patients: results of standardized interviews with the State Trait Anxiety Inventory and the Kessler 10 questionnaire. <i>Journal of Psychosomatic Obstetrics and Gynaecology</i> , 2020, 41, 122-130.	1.1	5
63	Possible Role of the Posterior Compartment Peritonectomy, as a Part of the Complex Surgery, Regarding Recurrence Rate, Improvement of Symptoms and Fertility Rate in Patients with Endometriosis, Long-Term Follow-Up. <i>Journal of Minimally Invasive Gynecology</i> , 2020, 27, 1103-1111.	0.3	11
64	Pre-operative serum CA125, peritoneal cancer index and intra-operative mapping score as predictors of surgical results in primary epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 62-66.	1.2	13
65	Unmet family planning needs among female refugees and asylum seekers in Germany — is free access to family planning services enough? Results of a cross-sectional study. <i>Reproductive Health</i> , 2020, 17, 115.	1.2	6
66	Delaying surgery for patients with a previous SARS-CoV-2 infection. <i>British Journal of Surgery</i> , 2020, 107, e601-e602.	0.1	96
67	Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors. <i>JAMA Oncology</i> , 2020, 6, 1923.	3.4	27
68	Post-operative management and follow-up of surgical treatment in the case of rectovaginal and retrocervical endometriosis. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 957-967.	0.8	6
69	Patients— subjective assessment as a decisive predictor of malignancy in pelvic masses: results of a multicentric, prospective pelvic mass study. <i>Journal of Psychosomatic Obstetrics and Gynaecology</i> , 2020, , 1-6.	1.1	0
70	Role of predictive markers for severe postoperative complications in gynecological cancer surgery: a prospective study (RISC-Gyn Trial). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1975-1982.	1.2	11
71	Nerve-Sparing Systematic Lymph Node Dissection in Gynaecological Oncology: An Innovative Neuro-Anatomical and Surgical Protocol for Enhanced Functional Outcomes. <i>Cancers</i> , 2020, 12, 3473.	1.7	3
72	Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB—IVA: oncologic results of a prospective randomized international multicenter (Uterus-11) intergroup study. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1855-1861.	1.2	66

#	ARTICLE	IF	CITATIONS
73	A Concise Paradigm on Radical Hysterectomy: The Comprehensive Anatomy of Parametrium, Paracolpium and the Pelvic Autonomic Nerve System and Its Surgical Implication. <i>Cancers</i> , 2020, 12, 1839.	1.7	13
74	LION-PAW (lymphadenectomy in ovarian neoplasm) sexual function assessment: a prospective sub-study of the LION trial. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1548-1553.	1.2	7
75	<i>BRCA1</i> Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1190-1203.	3.0	32
76	MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. <i>Journal of Clinical Oncology</i> , 2020, 38, 3753-3762.	0.8	82
77	Favorable therapeutic response after anti-Mesothelin antibody-drug conjugate treatment requires high expression of Mesothelin in tumor cells. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 1255-1262.	0.8	12
78	Soluble heat-shock protein 27 in blood serum is a non-invasive prognostic biomarker for ovarian cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 255, 154-159.	0.5	2
79	Results of the interprofessional and interdisciplinary Berlin round table on patient-reported outcomes, quality of life, and treatment expectations of patients with gynecological cancer under maintenance treatment. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1603-1607.	1.2	4
80	Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in <i>BRCA1/2</i> : results of the observational AGO-TR1 study (NCT02222883). <i>Journal of Medical Genetics</i> , 2020, , jmedgenet-2020-107353.	1.5	3
81	Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2020, 87, 102040.	3.4	35
82	Sexually assaulted women: Results of a retrospective analysis of 850 women in Germany. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 250, 117-123.	0.5	11
83	European Federation for Colposcopy (EFC) and European Society of Gynaecological Oncology (ESGO) joint considerations about human papillomavirus (HPV) vaccination, screening programs, colposcopy, and surgery during and after the COVID-19 pandemic. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1097-1100.	1.2	35
84	Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1997-2001.	1.2	11
85	EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM. <i>Molecular Cancer Research</i> , 2020, 18, 278-286.	1.5	12
86	Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 498-503.	1.2	14
87	The role of acculturation in migrants' use of gynecologic emergency departments. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 149, 24-30.	1.0	4
88	Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?. <i>Current Treatment Options in Oncology</i> , 2020, 21, 49.	1.3	7
89	Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 1267-1274.	0.8	3
90	Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 509-514.	1.2	9

#	ARTICLE	IF	CITATIONS
91	Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 699-709.	5.1	104
92	Adequate Utilization of Emergency Services in Germany: Is There a Differential by Migration Background?. <i>Frontiers in Public Health</i> , 2020, 8, 613250.	1.3	8
93	Total retroperitoneal en bloc resection of multivisceral-peritoneal packet (TROMP operation): a novel surgical technique for advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 648-653.	1.2	10
94	ERR&#x3B1; acts as a potential agonist of PPAR&#x3B3; to induce cell apoptosis and inhibit cell proliferation in endometrial cancer. <i>Aging</i> , 2020, 12, 23029-23046.	1.4	5
95	Association between obesity and vulvar cancer recurrence: an analysis of the AGO-CaRE-1 study. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 920-926.	1.2	3
96	Progress of evidence-based treatment decision support utilizing Molecular Health Guide in patients with gynecological solid tumors over three to six years. , 2020, 80, .		0
97	Predicting the course of disease in recurrent vulvar cancer â€“ A subset analysis of the AGO-CaRE-1 study. <i>Gynecologic Oncology</i> , 2019, 154, 571-576.	0.6	15
98	OVQUEST â€“ Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors. <i>Gynecologic Oncology</i> , 2019, 155, 126-134.	0.6	26
99	<p>Dual targeting of estrogen receptor Î± and estrogen-related receptor Î±: a novel endocrine therapy for endometrial cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6757-6767.	1.0	10
100	Transfusion of red blood cells does not impact progressionâ€free and overall survival after surgery for ovarian cancer. <i>Transfusion</i> , 2019, 59, 3589-3600.	0.8	13
101	Nerve-sparing radical hysterectomy: steps to standardize surgical technique. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1203-1208.	1.2	21
102	Impact of brief prewarming on anesthesia-related core-temperature drop, hemodynamics, microperfusion and postoperative ventilation in cytoreductive surgery of ovarian cancer: a randomized trial. <i>BMC Anesthesiology</i> , 2019, 19, 161.	0.7	9
103	Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation. <i>Biomedicine and Pharmacotherapy</i> , 2019, 118, 109371.	2.5	43
104	Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancerâ€”A Study of the GANNET53 Consortium. <i>Frontiers in Oncology</i> , 2019, 9, 832.	1.3	23
105	Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base. <i>Gynecologic Oncology</i> , 2019, 154, 539-546.	0.6	15
106	A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancer. <i>Archives of Gynecology and Obstetrics</i> , 2019, 300, 191-199.	0.8	16
107	Sialic Acid Linkage Analysis Refines the Diagnosis of Ovarian Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 261.	1.3	41
108	Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 537-560.	1.9	19

#	ARTICLE	IF	CITATIONS
109	Patients'™ perspectives towards malignant ascites: results of a prospective observational trial regarding expectations, characteristics and quality of life" a study of the North-Eastern-German Society of Gynecological Oncology. Archives of Gynecology and Obstetrics, 2019, 299, 1385-1389.	0.8	1
110	Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines. Biomedicine and Pharmacotherapy, 2019, 113, 108727.	2.5	53
111	Current practice and physicians'™ opinion about preoperative hair removal as a part of ERAS pathway implementation in gynecology and gynecology"oncology: a NOGGO-AGO survey of 148 gynecological departments in Germany. Archives of Gynecology and Obstetrics, 2019, 299, 1607-1618.	0.8	4
112	Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1063-1073.	1.2	14
113	A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms. New England Journal of Medicine, 2019, 380, 822-832.	13.9	373
114	Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study. Gynecologic Oncology, 2019, 153, 286-291.	0.6	20
115	Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network. Human Pathology, 2019, 85, 299-308.	1.1	24
116	Establishment of a Mucin Secreting Cell Line Cx-03 from an Uterine Carcino Sarcoma. Pharmaceutical Research, 2019, 36, 7.	1.7	1
117	Mesothelin as a target for cervical cancer therapy. Archives of Gynecology and Obstetrics, 2019, 299, 211-216.	0.8	13
118	Adequate utilisation of emergency services in Germany: a differential by migration background?. European Journal of Public Health, 2019, 29, .	0.1	0
119	Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer. Neoplasia, 2018, 20, 280-288.	2.3	23
120	Duration of storage influences the hemoglobin rising effect of red blood cells in patients undergoing major abdominal surgery. Transfusion, 2018, 58, 1870-1880.	0.8	13
121	Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1185-1195.	1.2	9
122	Expression III: patients'™ expectations and preferences regarding physician"patient relationship and clinical management"results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries. Annals of Oncology, 2018, 29, 910-916.	0.6	20
123	Risk factors for 30"day complications after cancer surgery in geriatric patients: a secondary analysis. Acta Anaesthesiologica Scandinavica, 2018, 62, 451-463.	0.7	5
124	The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study. BMC Cancer, 2018, 18, 476.	1.1	159
125	Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients" A study of the OVCAD consortium. Gynecologic Oncology, 2018, 149, 371-380.	0.6	11
126	Pain Mechanisms in Peritoneal Diseases Might Be Partially Regulated by Estrogen. Reproductive Sciences, 2018, 25, 424-434.	1.1	7



#	ARTICLE	IF	CITATIONS
127	Vulvar cancer in Germany: increase in incidence and change in tumour biological characteristics from 1974 to 2013. <i>Acta Oncologica</i> , 2018, 57, 324-330.	0.8	33
128	Regulation of matriptase and HAI-1 system, a novel therapeutic target in human endometrial cancer cells. <i>Oncotarget</i> , 2018, 9, 12682-12694.	0.8	9
129	Key regulator of cellular metabolism, estrogen-related receptor $\alpha$ , a new therapeutic target in endocrine-related gynecological tumor. <i>Cancer Management and Research</i> , 2018, Volume 10, 6887-6895.	0.9	8
130	GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis. <i>Nature Communications</i> , 2018, 9, 5224.	5.8	116
131	Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism. <i>British Journal of Cancer</i> , 2018, 119, 847-854.	2.9	24
132	Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer. <i>British Journal of Cancer</i> , 2018, 119, 1060-1066.	2.9	47
133	Potential role of the HOXD8 transcription factor in cisplatin resistance and tumour metastasis in advanced epithelial ovarian cancer. <i>Scientific Reports</i> , 2018, 8, 13483.	1.6	18
134	Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 842.	1.6	5
135	The genetic landscape of 87 ovarian germ cell tumors. <i>Gynecologic Oncology</i> , 2018, 151, 61-68.	0.6	44
136	Participation of elderly gynecological cancer patients in clinical trials. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 797-804.	0.8	9
137	Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).. <i>British Journal of Cancer</i> , 2018, 119, 330-338.	2.9	13
138	The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 521-528.	1.0	24
139	Preoperative Evaluation of Myometrial Invasion in Endometrial Carcinoma: Prospective Intra-individual Comparison of Magnetic Resonance Volumetry, Diffusion-weighted and Dynamic Contrast-enhanced Magnetic Resonance Imaging. <i>Anticancer Research</i> , 2018, 38, 4813-4817.	0.5	12
140	Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. <i>Lancet Oncology</i> , 2018, 19, 1117-1125.	5.1	95
141	The Role of PAR1 Autoantibodies in Patients with Primary Epithelial Ovarian Cancer. <i>Anticancer Research</i> , 2018, 38, 3619-3625.	0.5	9
142	The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis. <i>Gynecologic Oncology</i> , 2018, 150, 151-157.	0.6	21
143	Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , 2018, 19, 1247-1258.	5.1	79
144	Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5567-5567.	0.8	5

#	ARTICLE	IF	CITATIONS
145	Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor $\pm$ in high-grade serous ovarian carcinoma. <i>Human Pathology</i> , 2017, 67, 30-36.	1.1	11
146	Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 143-151.	1.4	2
147	Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSO). A study of the Ovarian Cancer Therapy "Innovative Models Prolong Survival (OCTIPS) Consortium. <i>European Journal of Cancer</i> , 2017, 79, 214-225.	1.3	29
148	A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO). <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 541-550.	1.2	16
149	A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7621-7632.	3.2	31
150	New associate Editor Prof. Dr. J. Sehouli for the section Gynecologic Oncology. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 1-1.	0.8	8
151	Prevention of palmo-plantar erythrodysesthesia in patients treated with pegylated liposomal doxorubicin (Caelyx <sup>®</sup> ). <i>Supportive Care in Cancer</i> , 2017, 25, 3545-3549.	1.0	11
152	Preference of elderly patients <sup>™</sup> to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial. <i>Gynecologic Oncology Research and Practice</i> , 2017, 4, 6.	3.6	9
153	Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2213-2222.	3.2	83
154	Cytoreductive surgery for ovarian cancer: quality assessment. <i>Annals of Oncology</i> , 2017, 28, viii25-viii29.	0.6	18
155	Endometriosis-associated Pain in Patients with and without Hormone Therapy. <i>Journal of Endometriosis and Pelvic Pain Disorders</i> , 2017, 9, 200-205.	0.3	3
156	Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test). <i>Journal of Ovarian Research</i> , 2017, 10, 72.	1.3	5
157	Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). <i>PLoS ONE</i> , 2017, 12, e0186043.	1.1	105
158	Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. <i>Oncotarget</i> , 2017, 8, 106415-106428.	0.8	42
159	Panitumumab in platinum-sensitive epithelial ovarian cancer patients with KRAS wild-type: The PROVE-study, a phase II randomized multicenter study of the North-Eastern German Society of Gynaecologic Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 5558-5558.	0.8	5
160	What are the expectations and preferences of patients with ovarian cancer to a maintenance therapy? A NOGGO/GCIG/ENGOT-ov22 survey (Expression IV) in 2101 patients. <i>Journal of Clinical Oncology</i> , 2017, 35, e17096-e17096.	0.8	5
161	High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism. <i>Oncotarget</i> , 2017, 8, 102912-102922.	0.8	57
162	New <i>in vitro</i> system to predict chemotherapeutic efficacy of drug combinations in fresh tumor samples. <i>PeerJ</i> , 2017, 5, e3030.	0.9	6

#	ARTICLE	IF	CITATIONS
163	The Impact of Surgical Staging on the Prognosis of Mucinous Borderline Tumors of the Ovaries: A Multicenter Study. , 2017, 37, 5609-5616.		12
164	Neutrophil Granulocytes in Ovarian Cancer - Induction of Epithelial-To-Mesenchymal-Transition and Tumor Cell Migration. Journal of Cancer, 2016, 7, 546-554.	1.2	42
165	Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells. Oncotarget, 2016, 7, 15648-15661.	0.8	13
166	Predictive and Prognostic Value of sPRR in Patients with Primary Epithelial Ovarian Cancer. Analytical Cellular Pathology, 2016, 2016, 1-6.	0.7	9
167	Characterization of endometriosis-associated immune cell infiltrates (EMaICI). Archives of Gynecology and Obstetrics, 2016, 294, 657-664.	0.8	56
168	Role of tumour-free margin distance for loco-regional control in vulvar cancer—a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study. European Journal of Cancer, 2016, 69, 180-188.	1.3	64
169	Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR). Annals of Oncology, 2016, 27, 2236-2241.	0.6	32
170	AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer. BMC Genomics, 2016, 17, 643.	1.2	19
171	Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium. Tumor Biology, 2016, 37, 12329-12337.	0.8	16
172	Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial. Annals of Oncology, 2016, 27, 1733-1739.	0.6	28
173	Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients—Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group. International Journal of Radiation Oncology Biology Physics, 2016, 94, 243-253.	0.4	33
174	A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse. Journal of Clinical Oncology, 2016, 34, 2271-2278.	0.8	114
175	Wilms tumor protein 1 (WT1) — Not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma. Gynecologic Oncology, 2016, 140, 494-502.	0.6	26
176	The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients—results from the OVCAD study. Tumor Biology, 2016, 37, 3009-3016.	0.8	23
177	The impact of preoperative malnutrition on surgery outcome and overall survival in ovarian or peritoneal cancer patients: A prospective study.. Journal of Clinical Oncology, 2016, 34, 5574-5574.	0.8	2
178	Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget, 2016, 7, 1486-1499.	0.8	212
179	Regional hyperthermia of the abdomen, a pilot study towards the treatment of peritoneal carcinomatosis. Radiation Oncology, 2015, 10, 157.	1.2	12
180	Somatic Copy Number Alterations Associated with Japanese or Endometriosis in Ovarian Clear Cell Adenocarcinoma. PLoS ONE, 2015, 10, e0116977.	1.1	28

#	ARTICLE	IF	CITATIONS
181	Systematic pelvic and paraaortic lymphadenectomy in early high-risk or advanced endometrial cancer. Archives of Gynecology and Obstetrics, 2015, 292, 1321-1327.	0.8	22
182	Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: A metaanalysis of four prospective randomised phase III trials with 5114 patients. European Journal of Cancer, 2015, 51, 825-832.	1.3	13
183	Polymorphism of the IL-8 gene and the risk of ovarian cancer. Cytokine, 2015, 71, 334-338.	1.4	33
184	Patient Empowerment Improved Perioperative Quality of Care in Cancer Patients Aged $\geq$ 65 Years – A Randomized Controlled Trial. PLoS ONE, 2015, 10, e0137824.	1.1	57
185	Prognostic and predictive value of primary vs secondary platinum resistance for bevacizumab treatment in platinum-resistant ovarian cancer in the AURELIA trial.. Journal of Clinical Oncology, 2015, 33, 5552-5552.	0.8	0
186	First results of Expression V Study, a survey by the North-Eastern-German Society of Gynaecological Oncology (NOGGO), assessing the therapy expectations of breast and ovarian cancer patients with different ethnicity in Germany.. Journal of Clinical Oncology, 2015, 33, e16582-e16582.	0.8	0
187	PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors. Anticancer Research, 2015, 35, 6329-34.	0.5	13
188	Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional Study. Anticancer Research, 2015, 35, 6869-75.	0.5	7
189	HIF1 $\alpha$ ; is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium. OncoTargets and Therapy, 2014, 7, 1563.	1.0	18
190	Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study. British Journal of Cancer, 2014, 111, 1519-1525.	2.9	9
191	Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer. Gynecologic Oncology, 2014, 135, 415-422.	0.6	38
192	Symptomization and triggering processes: Ovarian cancer patients' narratives on pre-diagnostic sensation experiences and the initiation of healthcare seeking. Social Science and Medicine, 2014, 119, 123-130.	1.8	21
193	BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients – A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). European Journal of Cancer, 2014, 50, 2090-2098.	1.3	75
194	Long-term follow-up of borderline ovarian tumors clinical outcome and prognostic factors. Anticancer Research, 2014, 34, 6725-30.	0.5	17
195	Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance – A study of the OVCAD consortium. Gynecologic Oncology, 2013, 128, 15-21.	0.6	107
196	Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer – a study by the OVCAD consortium. Gynecologic Oncology, 2013, 128, 38-43.	0.6	22
197	Conclusion. Future Oncology, 2013, 9, 41-41.	1.1	0
198	Discussion: session 1. Future Oncology, 2013, 9, 25-27.	1.1	2

#	ARTICLE	IF	CITATIONS
199	A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. <i>Annals of Oncology</i> , 2012, 23, 2265-2271.	0.6	72
200	Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives. <i>Annals of Oncology</i> , 2012, 23, 556-562.	0.6	22
201	A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study. <i>Annals of Oncology</i> , 2012, 23, 2259-2264.	0.6	34
202	A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer. <i>Gynecologic Oncology</i> , 2012, 124, 205-209.	0.6	17
203	Feasibility of Surgery After Systemic Treatment with the Humanized Recombinant Antibody Bevacizumab in Heavily Pretreated Patients with Advanced Epithelial Ovarian Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 1326-1333.	0.7	16
204	Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 242-248.	0.8	94
205	A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 861-868.	1.1	10
206	Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study. <i>Annals of Oncology</i> , 2010, 21, 2201-2205.	0.6	41
207	Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1331-40.	1.2	59
208	Use of paclitaxel for advanced ovarian cancer in clinical practice: analysis of 541 patients. Results from a German multi-centre observational study. <i>Anticancer Research</i> , 2010, 30, 4245-50.	0.5	3
209	Current role and future aspects of topotecan in relapsed ovarian cancer. <i>Current Medical Research and Opinion</i> , 2009, 25, 639-651.	0.9	28
210	Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. <i>Journal of Surgical Oncology</i> , 2009, 99, 424-427.	0.8	109
211	Pegylated liposomal doxorubicin (CAELYX®) in patients with advanced ovarian cancer: results of a German multicenter observational study. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 585-591.	1.1	26
212	Current management of borderline ovarian tumors: A multicenter survey of 323 clinics in Germany, on behalf of the North-Eastern German Society of Gynecological Oncology (NOGGO). <i>Journal of Clinical Oncology</i> , 2009, 27, e16568-e16568.	0.8	0
213	Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, multicenter trial of the North-Eastern German Society of Gynecological Oncology (NOGGO). <i>Journal of Clinical Oncology</i> , 2009, 27, 5553-5553.	0.8	1
214	Do patients with recurrent ovarian cancer benefit from relative tumor reduction? Results from a prospective study. <i>Journal of Clinical Oncology</i> , 2009, 27, e16541-e16541.	0.8	0
215	New aspects of adjuvant therapy in endometrial cancer: Current standards and future directions. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 67, 204-212.	2.0	15
216	Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 243-250.	1.1	30

#	ARTICLE	IF	CITATIONS
217	Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, two-stage phase-II study of the North-Eastern German Society of Gynaecological Oncology (NOGGO). <i>Journal of Clinical Oncology</i> , 2007, 25, 5526-5526.	0.8	5
218	Review of gemcitabine-based combinations for platinum-resistant ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 23-30.	1.2	14
219	Gemcitabine in Recurrent Ovarian Cancer. <i>American Journal of Cancer</i> , 2005, 4, 345-346.	0.4	0
220	Final analysis of weekly paclitaxel and weekly carboplatin (P) as first-line chemotherapy in 130 patients with advanced ovarian cancer (AOC). <i>Journal of Clinical Oncology</i> , 2005, 23, 5057-5057.	0.8	0
221	Dose Finding Study for Combination Treatment with Topotecan and Gemcitabine of Patients with Recurrent Ovarian Cancer after Failure of First-Line Chemotherapy with Paclitaxel and Platinum. <i>Oncology Research and Treatment</i> , 2004, 27, 58-64.	0.8	6
222	Biweekly schedule of pegylated liposomal doxorubicin (PLD) induces low rates of skin toxicities: Results of a phase-II trial in heavily pre-treated patients with relapsed ovarian cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 5072-5072.	0.8	1
223	Randomized Phase III trial: Topotecan vs. topotecan/etoposide vs topotecan/gemcitabine as second-line treatment for patients with relapsed ovarian cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 5139-5139.	0.8	1
224	Tumour biology in advanced ovarian cancer: Do older patients (>65 years) have other tumour characteristics than younger patients?. <i>Journal of Clinical Oncology</i> , 2004, 22, 5137-5137.	0.8	0
225	Randomized Phase III trial: Topotecan vs. topotecan/etoposide vs topotecan/gemcitabine as second-line treatment for patients with relapsed ovarian cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 5139-5139.	0.8	0
226	Biweekly schedule of pegylated liposomal doxorubicin (PLD) induces low rates of skin toxicities: Results of a phase-II trial in heavily pre-treated patients with relapsed ovarian cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 5072-5072.	0.8	3
227	Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients. <i>Anticancer Research</i> , 2004, 24, 1223-9.	0.5	73
228	Safety, tolerability and activity of gefitinib (ZD1839) in combination with tamoxifen in ovarian cancer patients refractory to platinum-taxane based therapy – a Phase-II study of the Ovarian Cancer Study Group (AGO Ovar 2.6). <i>Journal of Clinical Oncology</i> , 2004, 22, 5016-5016.	0.8	0
229	Tumour biology in advanced ovarian cancer: Do older patients (>65 years) have other tumour characteristics than younger patients?. <i>Journal of Clinical Oncology</i> , 2004, 22, 5137-5137.	0.8	0
230	A new therapeutical approach: Topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum. <i>Journal of Obstetrics and Gynaecology Research</i> , 2003, 29, 123-131.	0.6	9
231	Interleukin-1 receptor antagonist gene polymorphism is associated with increased risk of epithelial ovarian cancer. <i>Annals of Oncology</i> , 2003, 14, 1501-1504.	0.6	19
232	Detection of epithelial carcinoma cells in the blood of patients with gynaecological malignancies. <i>Anticancer Research</i> , 2003, 23, 1093-7.	0.5	3
233	Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study. <i>Anticancer Research</i> , 2003, 23, 1115-8.	0.5	19
234	Interleukin-1 receptor antagonist gene polymorphism in epithelial ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 1205-8.	1.1	8

#	ARTICLE	IF	CITATIONS
235	Prognostic significance of epithelial cells in the blood of patients with gynaecological malignancies. <i>Anticancer Research</i> , 2003, 23, 4133-40.	0.5	4
236	A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. <i>Annals of Oncology</i> , 2002, 13, 1749-1755.	0.6	28
237	First-Line Chemotherapy with Weekly Paclitaxel and Carboplatin for Advanced Ovarian Cancer: A Phase I Study. <i>Gynecologic Oncology</i> , 2002, 85, 321-326.	0.6	28
238	Operative Results after Primary and Secondary Debulking Operations in Advanced Ovarian Cancer (AOC). <i>Journal of Obstetrics and Gynaecology Research</i> , 1998, 24, 447-451.	0.6	46